PARTICIPATING RESEARCH INSTITUTIONS - Veglin

Press Release

May 11, 2011

Dr. Parkash Gill today announced that Veglin is not available until receiving further FDA approval. This delay is considered normal and a required process by the FDA. Once the FDA aproves, Alimta Cisplatin chemotherapy along with Veglin (a non-chemotherapy) will be the next protocol used.

    The Mesothelioma Research Foundation of America

    University of Southern California / Norris

Clinical Trials - participating sites

    Yale Cancer Medical Center